Bacteria-based bioactive materials for tumor immunotherapy
Precision Medicine and Engineering, ISSN: 2950-4821, Vol: 1, Issue: 2, Page: 100013
2024
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
As one of the most abundant biological populations endowed with unique properties such as specific targeting and genetic engineering vectors, bacteria with immunogenic potential have garnered significant attention for their ability to elicit immune activation against tumors. This approach has achieved substantial breakthroughs as a modality for cancer treatment and is known as bacterial immunotherapy. However, the immunosuppressive tumor microenvironment (TME) can inhibit the immune response induced by bacteria and promote tumor growth and metastasis. To overcome this challenge, recent advancements in bacteria-based bioactive materials, which are biological substances synthesized by bacteria, have not only harnessed the inherent properties of bacteria but also specifically targeted the modulation of the TME, providing a more favorable environment for immune activation and significantly enhancing the efficacy of immunotherapy for cancer treatment. This review introduces the key mechanisms of bacteria-based biomaterials as anticancer agents and reviews the latest research progress, along with their clinical applications in cancer treatment. Finally, the potential and challenges of bacteria-based biomaterials for tumor therapy are explored, aiming to provide insights into the functions of bacteria-based bioactive materials and their role in advancing cancer immunotherapy while offering recommendations for the development of new bacteria-based biomaterials.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know